Pancreatic Cancer Research

ResearcherTUM KlinikumActive in the last 2 years

Carolin Schneider

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3539-9026; OpenAlex author ID A5049595850, A5133840127. Sources: OpenAlex.

Their work

Papers
15 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
63
Papers, trials and grants by year

2021: 1 paper · 2022: 4 papers · 2023: 1 paper · 2024: 3 papers · 2025: 3 papers · 2026: 3 papers

Papers 15

  1. The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. First author DOI 10.1002/mco2.70794↗
  2. Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam. Co-author DOI 10.1158/2767-9764.crc-25-0670↗
  3. Spatially-resolved subtype progression reveals metabolic vulnerabilities in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-026-02628-3↗
  4. KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Co-author DOI 10.1002/1878-0261.13725↗
  5. PRMT5 inhibitors: Therapeutic potential in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2025.102366↗
  6. Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. Co-author DOI 10.1038/s41419-025-08362-w↗
  7. A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. Co-author DOI 10.1002/advs.202307695↗
  8. Stress granules-membraneless organelles as therapeutic targets in pancreatic cancer. Co-author DOI 10.1038/s44321-024-00040-2↗
  9. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies. Co-author DOI 10.1053/j.gastro.2023.10.026↗
  10. Epigenetic control of pancreatic cancer metastasis. First author DOI 10.1007/s10555-023-10132-z↗
  11. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. Co-author DOI 10.1002/cac2.12280↗
  12. AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. Co-author DOI 10.1007/s00018-022-04638-y↗
  13. HDAC2 Facilitates Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-20-3209↗
  14. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. Co-author DOI 10.1172/jci.insight.151353↗
  15. Insulin Receptor in Pancreatic Cancer-Crown Witness in Cross Examination. Co-author DOI 10.3390/cancers13194988↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Günter Schneider · 14 shared papers, 2022–2026 · strength 2.78
  2. Elisabeth Heßmann · 9 shared papers, 2022–2026 · strength 1.60
  3. Lukas Krauß · 9 shared papers, 2022–2026 · strength 1.42
  4. Dieter Saur · 9 shared papers, 2022–2026 · strength 1.42
  5. Maximilian Reichert · 9 shared papers, 2022–2026 · strength 1.32
  6. Matthias Wirth · 8 shared papers, 2022–2026 · strength 1.19
  7. Michael B. Ghadimi · 5 shared papers, 2024–2026 · strength 0.90
  8. Christian Schneeweis · 6 shared papers, 2022–2026 · strength 0.86
  9. Volker Ellenrieder · 5 shared papers, 2024–2026 · strength 0.84
  10. Marian Grade · 5 shared papers, 2022–2026 · strength 0.83
  11. Roland Rad · 6 shared papers, 2022–2026 · strength 0.81
  12. Constanza Tapia Contreras · 4 shared papers, 2024–2026 · strength 0.71
  13. Valentina Spielmann · 2 shared papers, 2025–2026 · strength 0.58
  14. Felix Orben · 4 shared papers, 2022–2026 · strength 0.57
  15. Lena‐Christin Conradi · 3 shared papers, 2025–2026 · strength 0.57
  16. Oliver Holger Krämer · 4 shared papers, 2022–2026 · strength 0.56
  17. Ulrich Sax · 3 shared papers, 2024–2026 · strength 0.49
  18. Zonera Hassan · 4 shared papers, 2022 · strength 0.48
  19. Roland Michael Schmid · 3 shared papers, 2022–2026 · strength 0.41
  20. Gabriela Salinas Riester · 2 shared papers, 2025 · strength 0.38
  21. Tiago De Oliveira · 2 shared papers, 2025–2026 · strength 0.36
  22. Janine Murr · 2 shared papers, 2022–2026 · strength 0.30
  23. Chiara Falcomatà · 2 shared papers, 2022–2024 · strength 0.26
  24. Bernhard Küster · 2 shared papers, 2022–2024 · strength 0.25
  25. Katharina Lankes · 2 shared papers, 2022 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.